Literature DB >> 19713740

Obesity promotes melanoma tumor growth: role of leptin.

Elizabeth L Brandon1, Jian-Wei Gu, Lauren Cantwell, Zhi He, Gray Wallace, John E Hall.   

Abstract

Epidemiological studies suggest that obesity increases the risk of developing several cancers, including melanoma. Obesity increases the expression of angiogenic factors, such as leptin, that may contribute to tumor growth. However, a direct cause and effect relationship between obesity and tumor growth has not been clearly established and the role of leptin in accelerating tumor growth is unclear. Our objective in the present study was to examine the rate of melanoma tumor growth in lean and obese mice with leptin deficiency or high levels of plasma leptin. We injected 1 x 10(6) B16F10 melanoma cells subcutaneously into lean wild type (WT), obese melanocortin receptor 4 knockout (MC4R(-/-)), which have high leptin levels, obese leptin-deficient (ob(-/-)), pair fed lean ob(-/-), and lean ob(+/-) mice. Mean body weights were 29.7 +/- 0.3 g (WT), 46.3 +/- 1.9 g (MC4R(-/-)), 63.7 +/- 0.9 g (ob(-/-)), 30.5 +/- 1.0 g (pair fed ob(-/-)) and 31.6 +/- 1.7 g (ob(+/-)). Tumors were much larger in the obese leptin deficient ob(-/-) (5.1 +/- 0.9 g) and obese MC4R(-/-) (5.1 +/- 0.7 g) than in lean WT (1.9 +/- 0.3 g) and ob(+/-) (2.8 +/- 0.7 g) mice. Prevention of obesity by pair feeding ob(-/-) mice dramatically reduced tumor weight (0.95 +/- 0.2 g) to a level that was significantly lower than in WT mice of the same weight. Tumor VEGF levels were the highest in the obese mouse tumors (p < 0.05), regardless of the host leptin levels. Except for the lean ob(+/-), MC4R(-/-) and ob(-/-) melanomas had the highest VEGF receptor 1 and VEGF receptor 2 protein expression (p < 0.01 and p < 0.05), respectively. These results indicate that obesity markedly increases melanoma tumor growth rate by mechanisms that may involve upregulation of VEGF pathways. Although tumor growth does not require host leptin, melanoma tumor growth may be accelerated by leptin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713740      PMCID: PMC2796478          DOI: 10.4161/cbt.8.19.9650

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  31 in total

1.  Leptin influences cellular differentiation and progression in prostate cancer.

Authors:  Kenan Saglam; Emin Aydur; Milker Yilmaz; Serdar Göktaş
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

2.  Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF.

Authors:  R Cao; E Brakenhielm; C Wahlestedt; J Thyberg; Y Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

3.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

4.  Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors.

Authors:  Margot P Cleary; Frederick C Phillips; Susan C Getzin; Tina L Jacobson; Michelle K Jacobson; Trace A Christensen; Subhash C Juneja; Joseph P Grande; Nita J Maihle
Journal:  Breast Cancer Res Treat       Date:  2003-02       Impact factor: 4.872

5.  Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor-alpha female mice.

Authors:  Margot P Cleary; Michelle K Jacobson; Frederick C Phillips; Susan C Getzin; Joseph P Grande; Nita J Maihle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-09       Impact factor: 4.254

6.  Adipose tissue mass can be regulated through the vasculature.

Authors:  Maria A Rupnick; Dipak Panigrahy; Chen-Yu Zhang; Susan M Dallabrida; Bradford B Lowell; Robert Langer; M Judah Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

7.  Overweight as an avoidable cause of cancer in Europe.

Authors:  A Bergström; P Pisani; V Tenet; A Wolk; H O Adami
Journal:  Int J Cancer       Date:  2001-02-01       Impact factor: 7.396

8.  Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.

Authors:  H Gogas; M Trakatelli; N Dessypris; A Terzidis; A Katsambas; G P Chrousos; E T Petridou
Journal:  Ann Oncol       Date:  2007-10-08       Impact factor: 32.976

9.  Prevalence and trends in overweight among US children and adolescents, 1999-2000.

Authors:  Cynthia L Ogden; Katherine M Flegal; Margaret D Carroll; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

10.  Prevalence and trends in obesity among US adults, 1999-2000.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

View more
  33 in total

Review 1.  Immunomodulation at epithelial sites by obesity and metabolic disease.

Authors:  Kitty P Cheung; Kristen R Taylor; Julie M Jameson
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

2.  Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

Authors:  Siyuan Xia; Ruiting Lin; Lingtao Jin; Liang Zhao; Hee-Bum Kang; Yaozhu Pan; Shuangping Liu; Guoqing Qian; Zhiyu Qian; Evmorfia Konstantakou; Baotong Zhang; Jin-Tang Dong; Young Rock Chung; Omar Abdel-Wahab; Taha Merghoub; Lu Zhou; Ragini R Kudchadkar; David H Lawson; Hanna J Khoury; Fadlo R Khuri; Lawrence H Boise; Sagar Lonial; Benjamin H Lee; Brian P Pollack; Jack L Arbiser; Jun Fan; Qun-Ying Lei; Jing Chen
Journal:  Cell Metab       Date:  2017-01-12       Impact factor: 27.287

Review 3.  Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome.

Authors:  Allison Betof Warner; Jennifer L McQuade
Journal:  Curr Oncol Rep       Date:  2019-07-01       Impact factor: 5.075

4.  Cutting Edge: Elevated Leptin during Diet-Induced Obesity Reduces the Efficacy of Tumor Immunotherapy.

Authors:  Katherine A Murphy; Britnie R James; Frances V Sjaastad; Tamara A Kucaba; Hyunjoon Kim; Erik L Brincks; Streamson C Chua; Andrew Wilber; Thomas S Griffith
Journal:  J Immunol       Date:  2018-08-22       Impact factor: 5.422

5.  Increased plasma levels of soluble vascular endothelial growth factor receptor 1 (sFlt-1) in women by moderate exercise and increased plasma levels of vascular endothelial growth factor in overweight/obese women.

Authors:  Kristina L Makey; Sharla G Patterson; James Robinson; Mark Loftin; Dwight E Waddell; Lucio Miele; Edmund Chinchar; Min Huang; Andrew D Smith; Mark Weber; Jian-Wei Gu
Journal:  Eur J Cancer Prev       Date:  2013-01       Impact factor: 2.497

6.  Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans.

Authors:  K N Aronis; K N Diakopoulos; C G Fiorenza; J P Chamberland; C S Mantzoros
Journal:  Diabetologia       Date:  2011-06-10       Impact factor: 10.122

7.  Body mass index and height and risk of cutaneous melanoma: Mendelian randomization analyses.

Authors:  Jean Claude Dusingize; Catherine M Olsen; Jiyuan An; Nirmala Pandeya; Matthew H Law; Bridie S Thompson; Alisa M Goldstein; Mark M Iles; Penelope M Webb; Rachel E Neale; Jue-Sheng Ong; Stuart MacGregor; David C Whiteman
Journal:  Int J Epidemiol       Date:  2020-08-01       Impact factor: 7.196

Review 8.  Hyperinsulinaemia in cancer.

Authors:  Emily J Gallagher; Derek LeRoith
Journal:  Nat Rev Cancer       Date:  2020-09-09       Impact factor: 60.716

9.  Role of BMI and hormone therapy in melanoma risk: a case-control study.

Authors:  Vincenzo De Giorgi; Alessia Gori; Imma Savarese; Antonietta D'Errico; Federica Scarfì; Federica Papi; Vincenza Maio; Piero Covarelli; Daniela Massi; Sara Gandini
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-13       Impact factor: 4.553

Review 10.  Obesity as an immune-modifying factor in cancer immunotherapy.

Authors:  Robert J Canter; Catherine T Le; Johanna M T Beerthuijzen; William J Murphy
Journal:  J Leukoc Biol       Date:  2018-05-15       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.